• SinglePoint is undertaking a B2B cultivation effort to help companies specializing in cannabidiol (CBD) products reach a larger national market
• In conjunction with a national distribution partner, SinglePoint is offering to growing CBD product companies the potential of entering mass-market stores such as CVS, Kroger and Dollar Tree
• The ‘Strategics’ program may be particularly helpful as shelf space in the booming CBD industry tightens
• Investment bank Cowen & Co. is predicting a CBD market revenue outlook of $16 billion by 2025, growing from $600 million-plus in 2018

Emerging technology cultivator SinglePoint Inc. (OTCQB: SING) is launching a national distribution program that fosters the retail network aspirations of fast-growing cannabidiol (CBD) product companies to get their products into consumers’ hands.

The ‘Strategics’ program will provide qualifying companies, with annual revenue above $2 million, a pathway to market through a national distribution partner that has nearly $2 billion in annual sales to mass-market stores such as CVS, Walgreens, Rite-Aid, Dollar General, Dollar Tree, Giant Eagle, Meijer and Kroger grocery stores, as well as a wide number of regional and national convenience stores.

“Until now, startup, established and fast-growing CBD product companies have faced tremendous challenges in growing their business beyond e-commerce and regional distribution due to the enormous capital and logistics involved,” SinglePoint President Wil Ralston stated in announcing the endeavor (http://ibn.fm/qa0uI). “We are excited to roll out our ‘Strategics’ marketing program with a major national distributor that is receptive to building a portfolio of fast-growing CBD products and providing those products to their established mass market clients.”

SinglePoint specializes in acquiring small-to-mid-sized companies that exhibit promising new technologies. SinglePoint’s focus on diverse market points offers investors the opportunity to back a wide assortment of assets, including payment processing, cannabis and blockchain technologies.

The reach of SING’s program to well-known wellness industry retail outlets could be a potential boon to companies as an expected tightening of shelf space occurs in parallel with the exponential growth of the CBD market. Analysts at New York-based investment bank Cowen & Co. recently forecast a CBD play revenue outlook of $16 billion by 2025 – a significant jump from 2018’s estimated $600 million to $2 billion in CBD sales, according to Forbes (http://ibn.fm/7ZFvT). Forbes conducted a poll of 2,500 people, finding that nearly 7 percent use CBD products and nearly 20 percent had at least sampled a CBD-infused beverage.

SinglePoint has already commenced screening prospective companies for the ‘Strategics’ program and forwarding qualifiers to the national distribution partner. SinglePoint is not currently identifying the national distributor because of industry competition and the need to preserve the prescreening process, but approved companies will have the opportunity to present themselves directly to the national distribution partner, the announcement indicates.

The ‘Strategics’ program offers the additional benefit of membership in SING’s SingleSource cooperative supply chain, which includes options for buying CBD distillate, CBD isolate, hemp flower and raw biomass materials at a competitive price using a simple process.

To apply for the program, the principals of companies are encouraged to reach out to Don@SinglePoint.com, utilizing the subject line “(Company Name) Strategic CBD Distribution,” or to call 855-203-3318 for more information.

For more information, visit the company’s website at www.SinglePoint.com

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://ibn.fm/SING

• Assay results from historical drill core strongly suggest additional tonnage at the Irgon property
• QMC continues to develop the Irgon property toward commercial production
• The global lithium-ion battery market is projected to eclipse $60 billion by 2024

Lithium is well known by consumers as being a necessary component of rechargeable lithium-ion batteries, which are essential to power electric vehicles and other smart, mobile devices. A recent report by Global Market Insights projects that the global lithium-ion battery market will surpass $60 billion by 2024 as the growing adoption of electric vehicles, coupled with government initiatives to promote sustainable, green technology, boosts the lithium sector (http://ibn.fm/uBt7n).

The Irgon lithium mine project of southeastern Manitoba is located within the Cat Lake-Winnipeg River Pegmatite Field, which also hosts the nearby, world-renowned Tantalum Mining Corporation of Canada (TANCO) operation. TANCO, a wholly owned subsidiary of Cabot Corporation, is one of North America’s most successful spodumene and rare element pegmatite-hosted mines.

The Irgon project is comprised of 22 contiguous mineral claims that encompass a total of 11,325 acres. The Irgon lithium mine is positioned only 20 kilometers north of the TANCO mine. As QMC moves forward, it is aggressively working toward having its Irgon lithium mine project become the company’s first property to reach production (http://ibn.fm/cygRM).

QMC Quantum Minerals Corp. (TSX.V: QMC) (OTC: QMCQF) (FSE: 3LQ) continues to explore several additional spodumene-bearing pegmatite dikes identified within its Irgon lithium mine property. The company recently received positive assay results from historical drill cores for two additional pegmatite dikes.

This historical drilling was undertaken on the Central and Mapetre pegmatite dikes, which are also situated within the Irgon lithium mine property. The core has been securely stored in the TANCO core facilities at the mine site since 1978. The 1978 core samples provided by TANCO had originally been analyzed only for their concentration of tantalum and tin. According to a news release (http://ibn.fm/DiOVp), although the dikes were visibly spodumene-bearing (lithium) rare-element pegmatites, TANCO had not been interested in the lithium concentration and therefore did not analyze any of the samples for this element.

QMC resampled the core and reanalyzed the samples for 56 elements, including lithium, and the company noted that it is “very pleased with the overall results as they confirm continuation to depth of the spodumene mineralization previously identified by QMC’s surface sampling.”

Results of the core indicated that the best Mapetre dike intersection returned 0.32 percent Li2O over 16.61 meters, including 0.52 percent Li2O over 8.69 meters. The best intersection from the Central dike returned 1.28 percent Li2O over 3.81 meters, including 2.97 percent Li2O over 1.22 meters. Two additional sample intervals from drill holes on the Central dike re-assayed 1.50 percent Li2O over 1.52 meters and 1.04 percent Li2O over 1.52 meters.

The company stated in the news release, “This strongly supports the fact that both the Mapetre and the Central dikes remain excellent targets to add to the total tonnage available on the Irgon property.” In addition, “these results demonstrate that there is significant exploration potential for the Irgon property to host other large, spodumene-bearing pegmatite dikes in addition to the Irgon dike, as the lithium-bearing Central and Mapetre dikes are located on opposite ends of a large, 1,100-meter (3,600-foot) long, 100-meter (328-foot) to 350-meter (1,148-foot) wide” historical soil geochemical anomaly identified by TANCO, the source of which was never identified or evaluated.

For more information, visit the company’s website at www.QMCMinerals.com

NOTE TO INVESTORS: The latest news and updates relating to QMCQF are available in the company’s newsroom at http://ibn.fm/QMCQF

• LXRP has expanded its cannabis product relationship with Nuka Enterprises’ 1906 brand
• DehydraTECH enables 1906 chocolates to deliver on both function and flavor
• The company is expecting a tenfold increase in sales with expansion to legal markets

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), the developer and out-licenser for the disruptive and cost-effective DehydraTECH, recently announced that it has expanded its cannabis product relationship with Nuka Enterprises LLC, maker of 1906 cannabis edibles for high-functioning adults (http://ibn.fm/d1Uuv).

Since its beginnings in 2016, 1906 chocolates have benefited from DehydraTECH technology. In three short years, Nuka has become Colorado’s fastest-growing edibles company, and 1906 chocolates are currently available in more than 200 dispensaries. The products have been highlighted in nationally recognized publications including Vogue, Penthouse, Cosmo and Huffington Post.

An article in Forbes (http://ibn.fm/jRN1D) outlines the process that the 1906 team follows to create high-quality chocolates that deliver an intense, targeted experience. “Cannabis is great plant medicine, but the experience has been so disjointed,” 1906 co-founder Peter Barsoom stated in the article. “You’d have a quality, organic, good-tasting strain of cannabis being paired with mediocre chocolate with no idea of how it would make you feel — or when [the effects] would kick in.”

Using Lexaria’s DehydraTECH allows the 1906 brand to continue to deliver on both function and flavor, thus providing the consumer with a consistent experience.

The DehydraTECH drug-delivery platform improves speed, taste and delivery of bioactive compounds. Lexaria out-licenses this edible technology to companies such as Nuka Enterprises to enhance already-established, high-quality brands or create new ones.

DehydraTECH offers healthier alternatives to smoking for the consumption of bioactive substances. The technology delivers 475 percent more CBD in 15 minutes than other conventional industry formulations. Using this technology, the onset of effects can be experienced in 15 to 20 minutes rather than the unpredictable 60-to-120-minute window that’s traditionally required.

“As the fastest growing edibles brand in Colorado, we believe a huge part of our consumer appeal is because of this fast-acting technology,” Nuka Enterprises CEO and co-founder Peter Barsoom said in a news release. “We look forward to continuing to innovate alongside Lexaria, whose technology is the best in the industry.”

Over the next 18 months, Nuka is expecting an estimated tenfold increase in product volume as it expands to additional legal markets. The 1906 brand currently offers six distinct formulations of select cannabis strains with targeted plant medicines and high-quality chocolate. Nuka is expected to begin to develop consumer products containing CBD that will be available across the U.S. marketplace. In addition to its original chocolate products, Nuka has acquired rights to use DehydraTECH to expand its product options to include candies, beverages, capsules and pills and topical creams.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• H1 2019 results reflect excellent operational execution: lowest cost of cultivation per gram among publicly reporting Canadian LPs, industry-leading adjusted gross margin and adjusted EBITDA (positive adjusted EBITDA for 3rd consecutive quarter in Q2 2019)
• On track to increase target production capacity to 113,000 kg/year by the end of 2019
• Well-positioned for Canada’s new edibles and derivative legalization expected in October 2019 with expanding production capacity, R&D and various strategic partnerships
• Invested in biosynthesis to produce cannabinoids without growing the plant at a fraction of cultivation costs
• Focused on developing further international partnerships, prioritizing the CBD market

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., a leading Canadian licensed producer (“LP”) of high-quality cannabis and extract-based products. Founded in 2013, Organigram is focused on producing high quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to expand the Company’s global footprint.

The Company has distribution arrangements in all 10 provinces. Organigram delivers industry-leading yields and maximizes quality cannabis production at the lowest cultivation cost per gram among publicly reporting Canadian LPs.

Financial Results

In Q2 2019, the Company reported record net revenue of C$26.9 million, cash cost of cultivation of C$0.65 per gram, industry leading gross margin of C$16 million or 60% and adjusted EBITDA of C$13.3 million or margin of 49%, positive for the third consecutive quarter.

Significant Expansion Plans with Streamlined Licensing Process

Located in Moncton, New Brunswick, Organigram’s production facility and research & development program includes a state of the art, indoor 3-tier cultivation system which maximizes facility square footage. Its Phase 4 expansion project is expected to be completed by the end of 2019 for increased target production capacity of 113,000 kg/year (249,000 lbs.). As the Company expands its cultivation and processing capacities, Organigram is able to file amendments to the existing facility and each new production area is largely a replica of previously licensed areas, which results in a relatively streamlined and predictable licensing process with Health Canada.

In addition to increased production capacity from Phase 4, Organigram’s Phase 5 expansion includes plans for additional extraction capacity and its own edibles facility. Construction is expected to be substantially completed in October 2019.

Proprietary Technology

The Company’s indoor facility allows for control of all critical facets of the lighting and environmental elements to drive maximum quality and yield in the plants. The Company’s in-house proprietary information technology system, called OrganiGrow, tracks grow cycles, environmental conditions and other factors to optimize cultivation.

Numerous design and automation improvements include automated potting, pre-roll and packaging machines, and larger propagation rooms with advanced environmental systems.

Well Positioned for Canada’s Legalization of Edibles and Other Derivatives Products

Through its facility expansions, partnerships and research and development, the Company is well-positioned to capture further growth from the legalization of edibles and derivative products expected in October 2019. Its initial product focus is on vaporizable products and edibles.

Organigram’s development of a shelf-stable, thermally stable, water-soluble and tasteless cannabinoid nano-emulsion formulation may provide for an initial onset of effect within 10 to 15 minutes in a beverage. Non-cannabis formulations with a similar molecule size are water-soluble in humans (i.e., absorbed through the bloodstream rather than requiring first-pass liver metabolism, which results in longer onset and duration uncertainty). The Company expects to receive research and development licensing in the near term, at which point testing will be conducted to confirm the onset and duration.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado for the development of commercial scale extraction and derivative product development in Canada. Organigram’s partnership with Canada’s Smartest Kitchen, a leader in food product development, will expand the Company’s edibles R&D program.

The Company recently announced a C$15 million investment commitment in a high-speed, high-capacity, fully automated production line with a capacity of 4 million kilograms of exceptional chocolate cannabis edibles per year.

Organigram also has a multiyear extraction contract with Valens GroWorks Corp. to produce extract concentrate for oils and other derivative products.

Disruptive Technology

Through its partnership with Hyasynth Biologicals Inc., a biotech company and leader in the field of cannabinoid science and biosynthesis, Organigram has invested in a potentially disruptive technology that uses patented yeast strains and enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation. Organigram views this investment as providing early access to what it expects to be the future of cannabinoid production – cost-effectiveness, purity and scalability.

International

Organigram believes there will be increasing demand for CBD in Canada and beyond. As such, the Company has invested in Alpha-Cannabis Germany (ACG) and expects to provide ACG with flower for conversion into extracts. ACG is a medical cannabis provider serving the largest legalized medical market in Europe. The Company anticipates entering into an agreement with ACB to purchase pure synthetic CBD isolate in the future.

Organigram is also invested in Eviana Health Corp. (CSE: EHC), a Serbian-based company with hemp farming and processing assets.

Experienced Executive Team

• CEO Gregory Engel has 30 years of national and international experience in pharmaceuticals, biotechnology, cannabis, and consumer packaged goods (CPG), and most recently served as CEO of Tilray Inc. where he was instrumental in the company becoming the first Canadian exporter of medical cannabis, as well as establishing several trailblazing industry standards
• Jeff Purcell, Senior Vice President of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods
• Tim Emberg, Senior Vice President of Sales and Commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and CPG industries
• Paolo DeLuca, Chief Financial Officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities
• Ray Gracewood, Senior Vice President, Marketing & Communications, has 15 years of experience in the marketing space and was senior Director of Dales and Marketing for Moosehead Breweries Ltd.

This profile contains certain non-IFRS performance measures including cash and all-in cost of cultivation per gram, net revenue, adjusted EBITDA, and adjusted gross margin which are not calculated in accordance with IFRS and may not be comparable to similar data presented by other companies. Please see the company’s Q2 2019 MD&A.

For more information, visit the company’s website at www.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

• The company recently filed an application for uplisting to the Nasdaq Capital Market
• SHRG looks forward to rapid growth and increased revenues on a global scale
• The company has announced changes to its board of directors as CFO Walters shifts focus toward the uplisting process

Sharing Services Global Corporation (OTCQB: SHRG), the diversified holdings company focused on reshaping how entrepreneurs in the direct-selling industry succeed, recently announced that it has filed an application for uplisting to the Nasdaq Capital Market. This move follows a recent name and stock symbol change to better reflect its brand, identity and strategic plan for global expansion in the direct-selling industry. The company is executing its mission to change the industry and elevate its entrepreneurs with best-in-class products and services.

“Elevating the listing of our common stock to the Nasdaq Capital Market will increase corporate visibility, improve liquidity and broaden awareness in the financial markets, which is an important step forward in our mission to enhance shareholder value as the company continues to grow,” Sharing Services Global CEO John “JT” Thatch stated in a news release (http://ibn.fm/h7I8D). “We have made significant progress in strengthening our financial performance, governance and liquidity in the last 18 months since rebranding and launching our first two companies to position us for continued growth and profitability. These actions, coupled with the impending rollout of additional products and strategic international expansion, will continue that growth and profitability. A listing on the Nasdaq Capital Market is a natural progression for the company and our shareholders.”

Thatch was appointed president and CEO of the company in March 2018. His previous success in corporate growth, acquisition, financing and negotiation make him a strong asset as SHRG looks forward to rapid growth and increased revenues on a global scale through the utilization of a Blue Ocean Strategy. This strategy consists of three steps:

1. Elevating home-based entrepreneurs;
2. Utilizing direct-selling channels to create 100 percent organic growth; and
3. Creating successful and independent business leaders.

Success with this strategy in the United States has paved the way for the company to enter Canada and look toward additional international markets such as Europe, Mexico and Asia. The strategy encourages entrepreneurs to move away from competing with one another and move toward creating new market opportunities. Live seminars and training events help increase the knowledge of the entrepreneurs around the world. Unique compensation and reward programs help these business leaders succeed.

The company is continuing to expand in leadership as well. In addition to the new appointment of Keith Halls and Kip Allison, Thatch announced that steps are in place to expand with four more independent additions to its board of directors (http://ibn.fm/7QgZ4). A search committee has already been commissioned to begin the selection process. In connection with this process, CFO Frank Walters has resigned from his position on the company’s board to focus his efforts on the Nasdaq uplisting process and continued growth of SHRG.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• CVGR is on track to complete its Brantford, Ontario, facility in the coming months; the company expects to receive a license to begin producing cannabis flower and oils
• CVGR CEO has praised new licensing regulations requiring applicants to have a fully built site
• CVGR maintains priority in the cannabis licensing queue and is currently completing the sale and leaseback of its facility

City View Green Holdings Inc. (CSE: CVGR) anticipates receiving a license from Heath Canada enabling it to turn its Brantford, Ontario, resource into an operational cannabis grow-and-extraction facility. CVGR also hopes to close on its LOI for a purchase-leaseback transaction of the property in the near future, calling for the new landlord to finance the required build-out and capital improvements needed to obtain Health Canada licenses (http://ibn.fm/ORX0k).

In addition, CVGR recently announced that the exterior, security fencing and interior of the facility have been completed, and, over Q2 and Q3 2019, the company plans to complete construction of initial cultivation and extraction rooms for the approval of Health Canada. CVGR has maintained its application status and priority in the licensing queue for Health Canada and will submit an evidence package prior to receiving a license (http://ibn.fm/PyEGd).

In a news release, CVGR CEO Ian MacDonald said, “Our build-out at the Brantford facility will be completed in the coming months, and we are confident our license will be granted shortly thereafter, so we can begin operations and provide the finest flower and oils in the cannabis industry.”

CVGR anticipates closing soon on its LOI for completion of a sale-leaseback of the Brantford facility. The company would exercise its option to purchase the Brantford property, then transfer that option to a financier. CVGR would then enter a five-year lease with a five-year renewable term. The company would have the right of first refusal to purchase the facility and property if the new owner decides to sell.

MacDonald praised new regulatory guidelines established by Health Canada that require license applicants to have a fully built site at the time of application. He believes the change will speed up approval and “the value of a license will increase significantly.”

Toronto, Canada-based CVGR is a vertically integrated, seed-to-sale cannabis company that’s planning to grow high-quality cannabis and produce extracts. The company anticipates producing, once legalized, edible products, distillates and water-soluble products for the beverage market. CVGR is focused on becoming a diversified company that will potentially acquire targets in the cannabis industry.

For more information, visit the company’s website at www.CityViewGreen.ca

NOTE TO INVESTORS: The latest news and updates relating to CVGR are available in the company’s newsroom at http://ibn.fm/CVGR

• TransCanna recently executed an LOI to acquire premier indoor cultivator Lyfted Farms
• Lyfted Farms also offers an SAAS (software-as-a-service) platform for cannabis
• TransCanna released a video tour of its 196,000 sq. ft facility in Modesto, California

With its proposed acquisition of Lyfted Farms Inc. of Modesto, California, TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) is showing that its search for synergies continues. The company, based in Vancouver, Canada, announced the execution of a non-binding letter of intent dated May 17, 2019, to acquire the business and assets of Lyfted (http://ibn.fm/wEN1P). The acquisition, when competed, will follow a raft of others as TransCanna continues to pursue its add-on strategy of building a branding and distribution network in California, America’s largest cannabis market. In other news, the company has made available to investors an eight-minute video, in which its CEO, Jim Pakulis, describes the features and benefits of the company’s recently acquired 196,000-square-foot cannabis facility (http://ibn.fm/EeXki).

The acquisition of Lyfted Farms would give TransCanna a finger in many pies. Lyfted Farms holds licenses from the state of California for nursery cultivation, commercial cultivation and distribution. The fast-growing company is well known in the California market. Presently, it offers a range of high-end flower that includes about 50 exotic and unique genetic strains, with cultivation managed by a team with over 20 years’ experience.

Lyfted Farms, in operation since 2015, appears to be the first outfit to have offered an SAAS (software-as-a-service) platform for cannabis. The Lyfted Mobile App (“LAAS”) connects users to cannabis shops and dispensaries, allowing them to order and manage purchases. Suppliers must be California-licensed distributors, distributor transporters or delivery services with approved Lyfted accounts.

In April 2019, TransCanna announced that it had completed the purchase of a 196,000-square-foot vertically integrated cannabis facility located in Modesto, California. The facility is a state-of-the-art installation that has just undergone a two-year, $8 million upgrade to the highest USDA food processing standards. About 30,000 square feet will be devoted to nursery cultivation, with most of the space being used for commercial cultivation, warehousing and related activities.

The facility’s USDA R40 wall paneling will provide better temperature and humidity control so that, while the outside temperature may be 100 degrees Fahrenheit, the inside temperature could be a pleasant 70 degrees, even without the air conditioning units on. The controlled environment means that there is no air flow between the facility and outside, while the DuctSox system provides even airflow distribution within the facility, which is crucial for growing healthy plants, as well as smell mediation. All lights in the cultivation rooms are LED and Title 24 compliant, and with a height of 18 feet, plants can be set three-high, increasing space utilization. These features contribute to a substantial differentiating factor for TransCanna, according to Pakulis.

For more information, visit the company’s website at www.TransCanna.com

NOTE TO INVESTORS: The latest news and updates relating to TCAN are available in the company’s newsroom at http://ibn.fm/TCAN

• VPR Brands partners with top names in the cannabis and CBD oil industries
• The company’s assets include issued U.S. and Chinese patents for atomization-related products
• VPR Brands recently reported increased revenues for Q1 2019

A technology holding company, VPR Brands LP (OTC: VPRB) operates in the electronic cigarette (e-cigarette) and personal vaporizer industry in the United States. The company’s assets include issued U.S. and Chinese patents for atomization-related products, including technology for medical marijuana vaporizers and e-cigarette products and components. Furthermore, VPR Brands engages in product development for the vapor or vaping market, including e-liquids.

Headquartered in Fort Lauderdale, Florida, the company partners with leading global brands to promote and fast-track its products into the vanguard of the industry. VPR Brands has a strong portfolio of diverse brands targeted toward numerous cannabis and CBD oil industry sectors (http://ibn.fm/AiNGv). VPR’s product lineup includes Helium, HoneyStick, Vaporin, Vaporx, GoldLine and GoldLine Hemp.

The Helium vaping product is a 50ml durable and squeezable bottle with a drip tip. Chilled at 20 degrees below room temperature, Helium is engineered to deliver 77 percent VG (vegetable glycerin). HoneyStick is the company’s lifestyle brand of upper-tier vaporizers that combines high tech, high performance, dependability and affordability. VPR’s Vaporin line delivers Sub Ohm series starter kits. Vaporin also offers multipacks of selected starter kits, coils and premium e-liquids for retail and dispensary operations.

VPR’s GoldLine Brand is a combination of premium ingredients and extracts united with the newest in technology to realize the ultimate selection of CBD- and hemp-based products. This product range features edibles, including gummies and pure honey sticks, tinctures, pre-rolled flower, vapable products and creams. Additionally, GoldLine hemp-only products are created without CBD.

With its varied and innovative product family, VPR Brands is steering a clear path to growth. It recently announced its 2018 full-year financial results, which included increased revenues and a narrowed net loss versus 2017. Revenues for the 12 months ended December 31, 2018, were $4,613,300. This represented an increase of almost 28 percent versus revenues of $3,610,379 recorded the year prior. The introduction of new products during 2018 was responsible for this growth (http://ibn.fm/2u98N).

Moreover, VPR Brands also recently announced its Q1 2019 financial results. Revenues for the three months ended March 31, 2019, and the same period in 2018 were $1,318,049 and $1,001,162, respectively. This impressive growth is due to increased marketing and advertising efforts (http://ibn.fm/GNO8m). VPR Brands continues to maintain strong gross operating margins of greater than 40 percent.

“The year 2019 is off to a solid start so far, and we are setting the company’s pace, which will allow us to remain focused on sustainable manageable growth,” VPR Brands CEO Kevin Frija stated in a news release. “We continue to invest in inventory and new products to be able to keep up with increased demand.”

VPR Brands continues to pioneer dynamic new products for the e-cigarette and personal vaporizer industry. The company offers investors the potential for ROI with its growth strategy focused on high-performance, high-quality products that build exponential brand equity, awareness and loyalty. With its visionary and experienced management team, VPR Brands is working to drive growth in an ever-changing sector.

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB

• IONIC’s sophisticated, premium vape pen line has earned a reputation as the top vape brand in Washington state
• The company’s acquisitions include a 140-acre farm in eastern Washington state that’s capable of producing 100,000 pounds of cannabis, as well as a licensed cannabis volatile extraction and manufacturing facility in California
• IONIC’s proprietary formulations of refined cannabis oils and distillates are used to create the popular Zoots Premium Cannabis Infused Edibles line

IONIC Brands Corp. (CSE: IONC) (OTC: ZRRRF) is a national cannabis holding company that’s building a multistate portfolio of award-winning premium and luxury brands in the cannabis space. Established in 2015, IONIC Brands is an industry leader with a proven ability to expand and operate multiple cannabis concentrate consumer brands in markets across the western United States.

The cornerstone brand of the company’s portfolio, IONIC, is recognized as the top vaporizer brand in Washington state and is currently available at dispensaries in Washington, Oregon, Nevada and California. The company recently signed a definitive agreement to acquire Natural Extractions Inc., also known as Zoots Premium Cannabis Infused Edibles, which is based in Washington state (http://ibn.fm/cI4wN). Zoots has developed consumer-proven formulas that will be preserved by IONIC Brands.

IONIC will be the first to launch Lucid Green Inc.’s revolutionary technology platform as an enrichment to the company’s Ionic Certified Clean Program, which guarantees that its cannabis products meet or exceed state mandates on pesticide testing. Lucid Green is designed to provide vital safety information to consumers with a simple smartphone scan of the QR code on a cannabis product, as detailed in a news release. Lucid Green provides access to a library of product specific insights instantaneously – including test results, dosage guidance, effects and more, while also providing IONIC loyalty rewards.

Distribution is a critical part of the cannabis supply chain in California, which is projected to grow from $3.7 billion in 2018 sales to $7.7 billion by 2021, according to Arcview Market Research (http://ibn.fm/Sl1wJ). To that end, Ionic recently signed an exclusive distribution agreement with Continuum, a California division of Origin House that delivers to more than 500 dispensaries in California. Origin House has the largest U.S. footprint of branded and distribution assets in North America, according to a news release (http://ibn.fm/R2ytP).

“IONIC Brands sought out the top distributor in California and given Origin House’s footprint, Ionic anticipates increased brand awareness, heightened demand for its products, and aggressive sales growth,” IONIC Chairman and CEO John Gorst stated in the release. “Our exclusive distribution agreement with Origin House distributor Continuum aligns with our strategy to build a multi-state, consumer-focused cannabis concentrate national brand portfolio focusing on the premium and luxury segments.”

IONIC Brands has also entered into a letter of intent to acquire the licensed cannabis volatile extraction and manufacturing assets of Kavry Management LLC, located in Adelanto, California. The licensed facility, near Los Angeles, fits the company’s strategic plan of vertical integration, Gorst stated in a news release (http://ibn.fm/JEvZQ).

“Securing this facility is a great foundation for IONIC Brands in California to advance our current premium luxury cannabinoid products,” Gorst continued. “We also see substantial development potential of new revenue streams through manufacturing in California.”

The company’s aim is to be the leader of the highest-value segments of the cannabis market by following its success on the West Coast with nationwide expansion. IONIC Brands is led by a team of successful entrepreneurs who are aggressively expanding the company by building a multistate, consumer-focused cannabis concentrate brand portfolio focusing on the premium and luxury segments of the cannabis industry.

For more information, visit the company’s website at www.IONIC.social

NOTE TO INVESTORS: The latest news and updates relating to ZRRRF are available in the company’s newsroom at http://ibn.fm/ZRRRF

• A presentation by INMB co-founder and CFO David Moss is slated for June 5 at 10:20 a.m., with one-on-one meetings also available
• The company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease
• INMB received a $1 million grant from the Alzheimer’s Association to fund XPro1595 research and upcoming clinical trials in patients with Alzheimer’s disease

INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness patients’ innate immune systems to fight diseases, will share results of recent clinical advancements at the upcoming Ninth Annual LD Micro Invitational scheduled to take place at the Luxe Sunset Boulevard Hotel, June 4-5 in Bel-Air, California. Co-founder and CFO David Moss will lead INmune Bio’s presentation, which is set for June 5 at 10:20 a.m. PT, and participate in one-on-one meetings at the event, according to a news release (http://ibn.fm/sfg3n).

INmune Bio is pursuing several novel drug candidates that utilize a precision therapy approach to treat unsolved problems in medicine. Among the company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease (http://ibn.fm/1LEh2). Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases, including cancer and Alzheimer’s disease/dementia, which currently affect an estimated 5.8 million Americans, according to the Alzheimer’s Association (http://ibn.fm/HFqZF).

INmune Bio has been recognized by the Alzheimer’s Association with a ‘Part the Cloud’ award that included a $1 million grant to further research into XPro1595 and the potential hope that it may bring to millions of patients with Alzheimer’s disease. INmune Bio expects to initiate an XPro1595 phase I clinical trial in patients with Alzheimer’s disease during the summer of 2019.

INmune Bio is also advancing several clinical trials featuring INB03 and INKmune – both of which are focused on “taking the brakes off” of the body’s innate immune system, making it a powerful weapon in the fight against cancer (http://ibn.fm/f5nhT). INB03 is a checkpoint inhibitor that targets cells resistant to immunotherapy to instead become therapeutically effective; INKmune primes a patient’s own natural killer cells to move from a resting state to an active state to attack and eliminate residual disease (lingering cancer cells) after cancer therapy.

INmune Bio recently posted its Q1 2019 financial results in a shareholder update, which highlighted the achievement of becoming the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on the Nasdaq Capital Market (http://ibn.fm/RbQor).

INmune Bio also announced a common stock purchase agreement with Lincoln Park Capital Fund LLC, a Chicago-based institutional investor, for up to $20 million (subject to the terms of the agreements with Lincoln Park), which includes an initial investment of $300,000 (http://ibn.fm/GVLri). The investment is in addition to an earlier investment made by Lincoln Park during INmune Bio’s first round of funding in 2017, when the company was private.

“This financing agreement provides flexibility to opportunistically access capital at our option under favorable terms to advance our innate immune therapies in cancer and Alzheimer’s disease,” Moss said in a news release, noting that the funds will specifically help advance the company’s drug development pipeline into phase II clinical trials.

To schedule a one-on-one meeting with INmune Bio and Moss anytime during the LD Micro Invitational, contact KCSA Strategic Communications at INmune@kcsa.com

For more information, visit the company’s website at www.INmuneBio.com

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB